Dr. Reddy’s Laboratories has launched hydroxychloroquine sulfate tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil (hydroxychloroquine sulfate) tablets, in the US market.
RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it has entered into a commercialization agreement with ParaPRO LLC (“ParaPRO”), an Indiana-based specialty pharmaceutical company, granting RedHill the exclusive rights to promote Esomeprazole Strontium Delayed-Release Capsules to gastroenterologists in certain U.S. territories.
Like its Canadian peer and model, Valeant, 2016 was an ugly year for Concordia International. The Ontario-based drugmaker today reported a $1.3 billion loss—$25.76 per share—on $816 million in revenue after taking a $1.1 billion impairment charge, mostly on products that are no longer paying off so well.
The company decided to end the trial because of the difficulties in getting enough patients enrolled. It indicates that the company still felt confident in its potential as a commercial product.
Despite getting a new chief executive, promising to pay down its debt, and overhauling its operations, the drugmaker has seen its shares lose 87 percent of their value in 2016. The year-to-date decline is bigger than any of Valeant’s peers belonging to the 60-member Standard and Poor’s 500 Health Care Index. The drop would also make it the eighth-worst on the 180-member Nasdaq Biotechnology Index, whose largest loser was Concordia International Corp. -- a drugmaker sometimes compared to Valeant. The bonds have plunged as well.
Concordia International Corp.’s $4.9 billion debt-fueled acquisition spree is coming back to haunt the Canadian drugmaker’s lenders.
Endo International Plc (ENDP.O) has discussed a sale of Paladin Labs Inc, its Montreal-based specialty pharmaceutical subsidiary, to Canadian drug maker Knight Therapeutics Inc (GUD.TO), people familiar with the matter said on Friday.